Search
Now showing items 1-10 of 22
Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?
(2018-04)
Background: A considerable number of people with multiple sclerosis (pwMS) live in low- and middle-income countries (LMIC), where lack of resource adversely affects access to effective disease-modifying treatment. Objective: ...
e-Health and multiple sclerosis: An update.
(2018-11)
e-Health (or digital healthcare) is becoming increasingly relevant in multiple sclerosis (MS) clinical management. We aim to review and discuss current status and future perspective of e-health in people with multiple ...
Alemtuzumab depletion failure can occur in multiple sclerosis.
(2018-06)
Alemtuzumab is a lymphocyte-depleting antibody and one of the most effective treatments for relapsing multiple sclerosis. However, it also causes loss of immune-tolerance leading to secondary autoimmunity and marked anti-drug ...
Association between pathological and MRI findings in multiple sclerosis.
(Elsevier/Science Direct, 2012-03-19)
Pathological evaluation is the gold standard for identifying processes related to multiple sclerosis that explain disease manifestations, and for guiding the development of new treatments. However, there are limitations ...
Magnetic resonance imaging correlates of neuro-axonal pathology in the MS spinal cord.
(2018-09)
In people with multiple sclerosis (MS), the spinal cord is the structure most commonly affected by clinically detectable pathology at presentation, and a key part of the central nervous system involved in chronic disease ...